Healius (HLS) AGM 2025 summary

Opening remarks and agenda

• Chair welcomed attendees, acknowledged traditional land owners, and outlined contingency plans for technical issues affecting the online platform.

• Introduced Board members, management, and external auditor present at the meeting.

• Confirmed quorum, meeting opening, and agenda, including Chair and CEO addresses, Q&A, and formal business.

• Explained procedures for questions and voting, both in-person and online.

Financial performance review

• Completed sale of Lumus Imaging for AUD 965 million, exceeding expectations and enabling full debt repayment and a special dividend of nearly AUD 300 million.

• Group revenue for Q1 FY 2026 increased by 4.2%, with pathology revenues up 3.9% and Agilex Biolabs up 13.8%.

• Committed to AUD 15–20 million in annualized support cost savings, with AUD 7.3 million achieved in FY 2025 and AUD 8.5 million planned for FY 2026.

• Labor costs expected to remain broadly flat year-on-year.

Board and executive committee updates

• Four new Non-Executive Directors appointed in the past year, with succession planning and board refreshment a key focus.

• New CFO Andrew Thomson appointed, succeeding Steve Humphries.

• Executive team strengthened with new appointments in customer, commercial, legal, and governance roles.